.png)
NextGen Omics, Tech & Data Europe 2026
Congress Centre Basel, Switzerland
Programme
Day
Integrating Xenium Spatial Transcriptomics Into Preclinical Research for High-Resolution Molecular Profiling
Industry Presentation Conference Room 6Spatial transcriptomics is transforming preclinical research by enabling the high-resolution mapping of gene expression within intact tissue architecture. The Xenium platform introduces a next-generation approach to in situ transcriptomic profiling, combining high sensitivity, subcellular resolution, and scalable multiplexing to interrogate complex biological systems.
We will present how Xenium Spatial Transcriptomics is being integrated into preclinical research workflows to deliver precise molecular insights across diverse application areas. By preserving spatial context while quantifying hundreds to thousands of RNA targets simultaneously, Xenium allows researchers to resolve cellular heterogeneity, identify rare cell populations, and characterise cell–cell interactions within their native microenvironment.
Optimizing NGS Workflows For Large-Scale Cohorts: Enhancing Sequencing Efficiency And Data Uniformity
Solution Provider Presentation Conference Room 7Scaling cohort studies requires balancing deep data with tight budgets. Discover how Twist’s high-uniformity target enrichment and multiplexing maximize sequencing efficiency and cut costs to accelerate precision medicine.
Navinci Presentation
Solution Provider Presentation Conference Room 6Single Cell Transcriptome Heterogeneity
Industry Presentation Conference Room 4Membranes, Proximities, And Clones: Unlocking Multi-Scale Spatial Biology For AI-Driven Precision Oncology
Industry Presentation Conference Room 3Computational pathology transforms standard immunohistochemistry into multi-scale spatial biology. We demonstrate how quantitative continuous scoring (QCS) extracts sub-cellular features such as membrane-to-cytoplasm staining intensity ratios, cell-neighborhood proximities, and clone-level tumor heterogeneity maps from single tissue sections. We illustrate how this framework has been applied in oncology clinical trials to derive predictive biomarkers and support companion diagnostic development—culminating in a first implementation proof-point of AI-driven precision medicine.
Predicting Cell Fate Decisions From Longitudinal Single-Cell Transcriptomics In Paediatric Acute Myeloid Leukaemia Patients
Industry Presentation Conference Room 6Zeiss Presentation
Solution Provider Presentation Conference Room 4Single Cell & Spatial Bioinformatics To Identify Tissue Specific Targets In Rheumatoid Arthritis
Industry Presentation Conference Room 3Multi-Omics: What Is The Ask From Precision Medicine?
Industry Presentation Conference Room 7- A Pivotal Need
- What is Real?
- Around the World: coming full circle
Utilising Spatial Biology In Pharma R&D
Panel Discussion Conference Room 4• Enhancing precision medicine in drug research
• Bridging research to clinical applications
• Facilitating Academia &
• Industry collaboration
Translating Omics Data To Clinical Trial Decisions
Panel Discussion Conference Room 6• Ensuring clinical developments in under-represented therapeutic areas
• When does omics data become robust enough to influence trial design
• Cross functional team requirements for success
Vizgen Presentation
Solution Provider Presentation Conference Room 3Submission required
DECIPHERing Genomic Data: Applying FAIR Principles & Standards For Clinical Impact
Industry Presentation Conference Room 7- Explore how FAIR data principles and community standards drive translation of research to clinical applications.
- Learn how global initiatives like the Global Alliance for Genomics and Health enable broad, responsible use of genomic data.
- Hear how DECIPHER exploits standards to provide real-world tools for advancing clinical discovery and patient benefit.
Population-Scale Single-Cell Atlasing For Next-Generation Blood Diagnostics
Industry Presentation Conference Room 7Single-cell genomics offers unprecedented resolution in blood diagnostics with potential for mechanistic understanding into underlying causes of blood abnormalities.
Population-scale single-cell atlases of human blood spanning ~6,000 individuals across multiple biobanks lay the groundwork for next-generation blood diagnostics and for detecting outlier phenotypes across tissues beyond blood
Turning Single Cell Insights Into Novel Targets
Panel Discussion Conference Room 5How to best use multi-omics data to gain new insights
Developing single cell and spatial data results into actional targets and biomarkers
Utilising rare single cells
N6 Presentation
Solution Provider Presentation Conference Room 7Practical Applications of Single-Cell Technologies in Drug Development
Industry Presentation Conference Room 5- A highlight of practical applications of single-cell technologies along the drug development pipeline
- Developing atlases to accelerate target ID and functional validation
- Moving past RNA to direct protein quantification on cells
Sequencing by Expansion (SBX) - An Ulta-Fast, Scalable, High-Throughput Single-Molecule Sequencing Technology
Solution Provider Presentation Conference Room 7Sequencing by Expansion (SBX), a single-molecule sequencing technology overcomes the typical signal-to-noise limitations of classical nanopore sequencing by using a biochemical conversion process to encode the sequence of a target nucleic acid molecule into an Xpandomer, a highly measurable surrogate polymer. Expanding over 50 times longer than the parent DNA templates, Xpandomers are engineered with high signal-to-noise reporter codes to enable facile, high-accuracy nanopore sequencing. We demonstrate the performance of SBX and present the specialized molecular structures, chemistries, enzymes and methods that enable it. The innovative molecular and systems engineering in SBX create a transformative technology to address the needs of existing and emerging sequencing applications. Here, we present an overview of various applications that benefit from the advantages of the technology, such as WGS, single-cell sequencing, or proteome analyses.
Overcoming Computational Challenges Of Bioinformatics In Single Cell & Spatial Research
Panel Discussion Conference Room 3• Application of advanced AI models to complex bioinformatics challenges
• Integration and optimisation of deep learning methodologies
• Ensuring high standards of accuracy, computational efficiency, and interpretability in analytical outcomes
Aspect Analytics Presentation
Solution Provider Presentation Conference Room 4Multi-Omics Under Constraint: Whole Transcriptome and Exome Sequencing Workflows for Challenging Clinical Samples
Solution Provider Presentation Conference Room 6• Whole blood and tumor FFPE represent the vast majority of clinical trial samples collected for molecular analysis in oncology trials, yet these sample types pose several challenges for molecular analyses.
• We present robust workflows for whole transcriptome and exome sequencing that are compatible with low-input and variable-quality RNA and DNA. Through dedicated titration experiments, we investigated how input and quality impact gene expression profiles and variant calling sensitivity, revealing assay performance under sample constraints.
• These workflows enable robust gene expression quantification and accurate variant calling for exploratory analysis in clinical trials
Best Practices for Single Cell Sequencing
Solution Provider Presentation Conference Room 5In this session, we’ll cover how to choose the right single-cell sequencing technology for your research goals, highlight key sample handling and storage considerations, and share practical guidelines for planning and validating your experiments. Learn how to set your project up for success with insights drawn from Single Cell Discoveries’ extensive experience in single-cell and spatial transcriptomics.
One Graph To Rule Them All: Universal “Tree-Of-Life” Pangenomes
Workshop Conference Room 6Recent breakthroughs in sequencing technologies (read accuracy and length) and assembly algorithms are making complete telomere-to-telomere genomes a reality across the tree of life. As genome quality and scale continue to improve, we can now capture genetic diversity with unprecedented resolution, paving the way for species-wide pangenomes and a new era of genomic discovery.
Fractal-based pangenome graphs eliminate dependence on static reference genomes, enabling a single immutable graph to represent all individuals across all species. This tree-of-life structure provides universal coordinates compatible with BAM files, removing the need for species-specific, individual-specific, or chromosome-specific references in genomic analyses.
Decoding Placental Dysfunction: From Single-Cell Multi-Omics To Human Disease Models
Industry Presentation Conference Room 5Single-cell & multi-omics: Mapping disease-associated placental cell states with trophoblast dysfunction to identify key molecular and transcriptional drivers
Cellular senescence: Linking placental aging to maternal vascular dysfunction
Biomarker discovery: Connecting placental signals to maternal circulation
Introducing Same-Cell Biology: Live-Cell Sequencing and Precision Genome Editing via FluidFM®
Solution Provider Presentation Conference Room 5FluidFM® OMNIUM enables Same-Cell Biology: non-destructive cytoplasmic biopsies (Live-seq) and Impossible Genetic Edits via intranuclear CRISPR delivery (CellEDIT) on the same living cell, revealing true causal drivers behind cell fate and disease.
Decoding Tissue Complexity: Integrated Pipelines for Spatially Resolved, High-Dimensional Analysis and Comprehensive Reporting
Solution Provider Presentation Conference Room 4Understanding the complexity of tissue architecture and cellular interactions remains a central challenge in modern biology, particularly in oncology. Spatial context, functional cellular heterogeneity and cell states are key determinants of disease progression and therapeutic response, yet remain difficult to comprehensively capture and interpret empirically. Here, we present a tailored end-to-end pipeline that integrates advanced wet-lab methodologies with AI-supported computational analysis to translate tissue sections into high-dimensional, biologically meaningful data. This approach combines multiplex immunofluorescence imaging with carefully established and validated antibody panels, enabling detailed spatial phenotyping at single-cell resolution. The generated data are processed using dedicated bioinformatics and machine learning frameworks designed to support data interpretation and facilitate structured, comprehensive reporting. By integrating expertise in pathology, immunology, and computational biology, the pipeline aims to bridge the gap between complex spatial data generation and downstream analysis. The workflow has been applied in both exploratory research settings and translational contexts, with a primary focus on cancer biology and precision medicine. It provides quantification of tumor microenvironments, cellular interactions, and potential biomarkers / targets relevant to treatment strategies as well as tentative summary interpretations. Overall, this approach provides a scalable framework for the analysis of complex tissue samples, contributing to improved accessibility and interpretability of high-dimensional spatial data.
From Undruggable To Actionable: Transcriptomic Discovery Of Small-Molecule Modulators Of Oncogenic Transcription Factors
Industry Presentation Conference Room 6QUANTRO developed a Transcriptomic Discovery Platform that matches time-resolved transcriptional profiles triggered by small molecules with those from acute target degradation. This approach identifies direct inhibitors, modulators, and degraders of previously undruggable transcription factors and signaling nodes, with active discovery campaigns against c-MYC and YAP/TEAD.
Adoption Of AI For Spatial Analyses In Clinical Workflows
Industry Presentation Conference Room 6A system-wide transformation enabling whole slide imaging, standardisation, and enhanced collaboration across health boards in Wales.
Digitisation improved workflow efficiency through remote reporting, rapid case sharing, and better teaching and training.
AI integration, particularly in prostate, breast, and gastric pathology, demonstrated high diagnostic accuracy, reduced variability and improved efficiency in the process.
Large-scale deployment showed improved detection rates, reduced turnaround times, and increased diagnostic confidence.
Overall, AI acts as a decision-support tool, augmenting pathologists while highlighting the need for robust data, validation, and governance.
Unlocking Population Genomics With Large Scale Cohort Studies
Panel Discussion Conference Room 7Precision Immunology Using Computational Workflows And Machine Learning
Industry Presentation Conference Room 3*Using nf-core for scalable and reproducible pre-processing
*Deep learning for assessing the immune receptor repertoire
*Use cases in cancer and autoimmune diseases
Unlocking Novel Therapeutic Strategies Using Somatic Genomics
Industry Presentation Conference Room 6Somatic mutations occur after conception and accumulate throughout our lifespan. This creates a massive genetic diversity among our cells and drives differential cellular responses to selective pressures. Some somatic mutations cause or drive vulnerability to disease, others have a protective effect. By assessing these mutations in human disease, Quotient is uncovering novel disease insights and therapeutic strategies.
Translating Single-Cell Data To Mechanistic Insights For Pre-Clinical Safety Assessment
Industry Presentation Conference Room 4Use single-cell omics to identify the specific cell types/states driving pre-clinical observations and link them to pathways/MOT
Case studies where single-cell readout resolve uncertainty
How these mechanistic insights strengthen weight-of-evidence for safety assessment
Building Integrated Precision Diagnostics Of The Future – Uniting Biomarkers, CDx, Spatial Biology & AI
Panel Discussion Conference Room 5Creating a unified precision medicine ecosystem that improves patient stratification and treatment selection
How spatial biology and multimodal datasets are reshaping our understanding of disease mechanisms, tumor heterogeneity, and therapeutic response
Key challenges to scaling next-generation precision diagnostics
Leveraging Population-Scale Genomics & Health Registers For Clinical Discovery
Keynote Conference Room 6• FinnGen is a large-scale public–private partnership combining genomic data with longitudinal health registry
data from over 500,000 participants in Finland
• The Nordic health register system enables lifelong follow-up of healthcare events since the 1960s, providing
unique opportunities to study disease onset, progression, and outcomes the genetic characteristics of the Finnish
population, together with close collaboration between academia, biobanks, hospitals, and 15 international
pharmaceutical companies, enable novel insights into disease mechanisms and translational research
From Spatial Maps To Actionable Biomarkers: Direct Cell Isolation With SLACS
Solution Provider Presentation Conference Room 4Spatial biology has transformed our understanding of tissue architecture, yet identifying biologically important cells is only the first step. Functional biomarker discovery requires direct molecular characterization of those precise cells. This presentation introduces Spatially Resolved Laser Activated Cell Sorting (SLACS), a technology that enables rapid, image-guided isolation of individual cells or cellular regions from intact tissues while preserving their spatial context for downstream genomics, transcriptomics, proteomics, and multi-omics analyses. Through applications in cancer, immunology, and precision medicine, SLACS bridges the gap between spatial observation and molecular validation, enabling researchers to discover clinically relevant biomarkers that conventional dissociative or imaging-only approaches cannot readily access. The presentation will highlight how spatially targeted cell isolation provides a practical pathway from tissue morphology to actionable biological insights.
Using Large Precision Health Datasets To Support R&D Activities
Industry Presentation Conference Room 7Leveraging Population-Scale Genomics & Health Registers For Clinical Discovery: FinnGen Case Study
Industry Presentation Conference Room 7FinnGen is a large-scale public–private partnership combining genomic data with longitudinal health registry data from over 500,000 participants in Finland.
The Nordic health register system enables lifelong follow-up of healthcare events since the 1960s, providing unique opportunities to study disease onset, progression, and outcomes the genetic characteristics of the Finnish population, together with close collaboration between academia, biobanks, hospitals, and 15 international pharmaceutical companies, enable novel insights into disease mechanisms and translational research
Solving The Multiplex IF Bottleneck: From Antibody To Validated Panel
Solution Provider Presentation Conference Room 3Multiplex immunofluorescence should accelerate biomarker discovery, not slow it down with antibody conjugation, iterative staining cycles, and months of panel optimization. For many translational and pharma research teams, these barriers make custom multiplex panels difficult to develop, validate, and scale. This webinar introduces a simplified approach to multiplex protein detection: no antibody conjugation, no iterative staining, and a single staining cycle built on standard workflows you already know. You'll see how this reduces assay setup time and lowers the barrier to building custom panels. You'll also hear directly from an experienced spatial biology service laboratory about what it actually takes to validate a new multiplex workflow for real-world use, including early results from an antibody-drug conjugate (ADC) panel now in development, and the repeatability and robustness data behind it. Whether you're building a panel in-house or evaluating a validated service partner, you'll leave with a clearer picture of what's possible now, and what to look for as you move forward.
Vizgen Workshop
Industry Presentation Conference Room 6From Maps to Medicines: Lessons Learned from Spatial Multi-Omics and the Evolution of MiND-MAP for Therapeutic Target Discovery in Parkinson's Disease
Industry Presentation Conference Room 6* The challenges of drug target discovery in neurodegenerative diseases
* Why the field could benefit from spatial
* Lessons learned from spatial technology evaluations made in the past and their suitability for performing drug target discovery for neurodegenerative diseases
* Defining a clear biological hypothesis and experimental design in neuroscience
* Application of Muna's next generation MiND-MAP platform on Parkinson's disease
Data Standardization In Spatial Omics
Roundtable Discussion Conference Room 4Building The Infrastructure for Data-Driven Precision Medicine: The Role Of European Biobanking Networks
Industry Presentation Conference Room 7GESTALT Presentation 2: Spatial Transcriptomics: Showcase Studies
Industry Presentation Conference Room 4GESTALT Presentation 1: New Bases For Quality Control In Imaging Transcriptomics
Industry Presentation Conference Room 4Start-Up Zone Presentation: Beyond the Spatial Data Tsunami: Building the Infrastructure for Spatial Biology at Scale
Solution Provider Presentation Conference Room 3Start Up Zone Presentation: Patient Stratification in Endometriosis: From Heterogeneous Biological Data to Smarter Clinical Trials
Solution Provider Presentation Conference Room 3Single-Cell Epigenetic Profiling Of Formalin-Fixed Paraffin-Embedded Samples
Industry Presentation Conference Room 5Developing single-cell epigenetic profiling technologies for FFPE samples.
Enabling high-resolution analysis of chromatin accessibility in archived clinical tissues.
Revealing cellular and epigenetic heterogeneity in driving tumor relapse/metastasis .
The Olink Data Ecosystem: Integrating Data Across Omics from Discovery to Translation
Solution Provider Presentation Conference Room 3Kristin will discuss how complementary proteomic approaches and population-scale datasets can be brought together within a broader multi-omic context to support biological interpretation and more confident decision-making.
King’s Smart Trials Hub: Transforming Personalised Medicine for Complex, Heterogenous Disease
Industry Presentation Conference Room 4Clinical trials often fail to reflect the biological diversity of the patients they aim to treat, limiting the identification of predictive biomarkers and therapeutic response. The Smart Trials Hub, an open-access multi-omics facility at King's College London's Guy's Hospital, addresses this challenge by integrating spatial and non-spatial omics with patient-derived organoids and ex vivo tissue models within a unified, patient-specific pipeline. Combined with machine learning, this approach links molecular features to treatment response, identifies mechanisms underlying non-response, and enables biomarker and target discovery. This infrastructure provides a scalable framework for advancing predictive biomarkers and personalised medicine across diverse diseases.
Translational AI And AI-Factories To Predict Clinical Responses At Patient Level
Industry Presentation Conference Room 6• Bridging AI and translational impact
AI can help close critical gaps in translational science by connecting cutting-edge model development with portfolio-impactful applications, accelerating innovation across research and clinical development.
• Driving AI adoption in biomedicine
Cultural inertia remains a major barrier to AI adoption. AI-first frameworks, grounded in deep domain expertise, can accelerate deployment, improve decision-making, and create competitive advantage.
• An AI factory for patient response prediction
I will present an AI factory that predicts immunotherapy response from baseline blood samples. By combining single-cell RNA-seq, clinical data, molecular foundation models, and multi-instance learning, we generated patient-level embeddings that enabled accurate response prediction.
Ensuring AI Safety With Genomic Data
Industry Presentation Conference Room 7Revolutionizing Multi-Omics With Artificial Intelligence
Panel Discussion Conference Room 6• Changing ways of thinking with the
opportunities provided by AI
• What ‘unanswerable’ questions could be
reconsidered?
Data Governance & Large-Scale Cloud Platforms
Industry Presentation Conference Room 8Single-cell at Pharma Scale: Faster Analysis, Better Use of Your Data
Solution Provider Presentation Conference Room 6For single-cell core facilities in pharma, analysis and interpretation need to keep pace with sample throughput and requests across therapeutic areas. Nygen gives core scientists a shared environment to assess data quality and review cell-type and cell-state annotations, working alongside bioinformatics and therapeutic-area teams. Starting from count matrices, our platform supports hundreds of millions of cells and has delivered US$300,000 in annual savings for a pharma customer. This talk presents the computational performance, annotation reliability and data security behind these workflows, showing how cores reduce repeated work and make better use of their data for drug discovery and cell therapy.
Glencoe Software Presentation
Solution Provider Presentation Conference Room 8Scalable Multi-Omics Integration: Harnessing Cross-Species Data for Diagnostic Discovery
Solution Provider Presentation Conference Room 8Bio|Mx combines public and proprietary multi-omics datasets to uncover novel disease targets and diagnostic biomarkers. Through a case study on companion animal kidney disease, this session demonstrates how modern machine learning bridges translational gaps across species to deliver actionable healthcare solutions.
Foundational Human Health Longitudinal Models: Identifying Novel Disease Progression Targets in Metabolic Diseases
Industry Presentation Conference Room 6Disease Progression Biology: Our foundational models use large-scale longitudinal health data to move beyond coarse clinical labels and uncover causal biology.
Enhanced Discovery: End-to-end genetic discovery on redefined phenotypes increases signal density, achieving up to a 4-fold improvement in Phase II–III transition likelihood over traditional methods.
Expanded Target Landscape: We utilise longitudinal latents to identify novel, tractable targets across shared metabolic and cardiometabolic indications.
Deciphering the Mechanism of Action of a BRD9 Targeted GlueTM Degrader Using Multi-Omics
Industry Presentation Conference Room 8Amphista Therapeutics is developing a proprietary Targeted Glue™ technology, which induces degradation by target-assisted E3 ligase recruitment.
In this presentation, I will showcase how Amphista is applying multi-omics approaches for understanding degraders’ mode of action and guiding pharmacodynamic biomarker development.
As an example, I will use Amphista’s clinical development candidate for acute myeloid leukemia (AML), which targets the epigenetic regulator BRD9.
Keeping Patients At The Centre Of Data-Driven Precision Medicine
Panel Discussion Conference Room 8(AI)thena: An AI-Ready Oncology Data Foundation Enabling Multimodal Insights at Scale
Industry Presentation Conference Room 8Creating a FAIR data foundation: Brings multimodal oncology data together with standardized ontologies, automated quality controls, and unified governance.
Accelerating insight generation for oncology projects: Makes high-quality data easier to find, access, curate, and reuse, supporting cross-trial biomarker analyses, patient stratification, model benchmarking, and treatment-response prediction.
Driving an AI-ready-by-design culture shift: Applies novel technologies (AI) to the data strategy and implementation process, making data readiness and AI enablement integral to how oncology data is warehoused and delivered for consumption.
From Cancer Complexity To Personalized Medicine: New Paradigms For Biomarker Discovery
Industry Presentation Conference Room 8This talk will explore how integrating cancer complexity with multi-omics data, clinical information, and computational modelling can redefine biomarker discovery and personalized medicine. Ultimately, all these advances converge toward a single goal: improving patient outcomes through more precise and adaptive therapies. In this context, technology, including artificial intelligence, advanced imaging, and computational platforms is a crucial instrument that enables science to observe, interpret, and act upon the hidden complexity of cancer
Featured AI Session: Agentic AI in the Clinic: How LLM Co-Pilots Will Reshape Diagnostic Workflows
Industry Presentation Conference Room 8Large language models are evolving from passive assistants into agentic co-pilots that reason across imaging, pathology, genomics, and clinical text. This talk shows how LLM-based agents can structure tumor boards, match patients to trials, and orchestrate diagnostic workflows at the point of care - and what foundation models, evaluation, and regulation must deliver to make this clinically real.
Featured AI Session: A Year Of Using AI In Routine Diagnostics – How Did It Change Us?
Industry Presentation Conference Room 8The TUM Institute of Pathology uses AI for prostate cancer detection since 2025 in routine diagnostics. Many things had to be prepared for that, including the setup of a digital infrastructure and proper workflow change management. But was it worth the effort? We shed light into the implications and effects of digital and AI-supported sign-out.
Featured AI Session: From Algorithm To Routine Practice: Building A Repeatable Implementation Pipeline For AI In Pathology
Industry Presentation Conference Room 8FAIRness—And Then What? Building infrastructure For Reuse: A Disease-Specific Example In Kidney Disease
Industry Presentation Conference Room 8Using kidney disease and NURTuRE as a case study, this presentation explores why FAIR data alone do not guarantee meaningful reuse. It considers the connected infrastructure needed across discovery, access, governance, standards, multi-omics, stewardship and community, and how research outputs can be returned to create lasting value.
Multi-Omics Data Made Ready For AI: A Clinical Genomics Perspective
Industry Presentation Conference Room 6Multi-omics data is heterogeneous and complex, especially if it is generated in clinical settings, where diverse questions about patients’ phenotypes and experiments are part of the daily practice. In this talk, we will focus on how to empower domestic multi-omics data access and mining with capabilities of LLM and AI.
Representation Learning For Single-Cell Phenomics: From Immune Health To Organ-on-Chip Systems
Industry Presentation Conference Room 6•Representation learning for single-cell phenomics across biological scales by integrating microscopy-derived cellular phenotypes with molecular data
•Self-supervised and spatiotemporal AI approaches for immune-health profiling and organ-on-chip systems
•Applications in functional aging analysis, disease modeling, patient stratification, and predictive phenotyping
From Pixels To Biomarkers: Open Infrastructure And Expert Image Analysis, Made In Europe
Industry Presentation Conference Room 8Multiplexed imaging is generating more data than biomarker programs can manage. Whole-slide images vanish into closed platforms, storage is resold at a premium, and every transfer or integration becomes a project in itself. This talk presents a different architecture: cytario, an open-source, S3-native platform where your data never leaves your own bucket and the file itself is the interface. No proprietary APIs, no adapters, no lock-in. We show mIF-first viewing in the browser, from 16-bit rendering to million-cell segmentation overlays, and how expert image-analysis teams deliver per-marker, pathologist-verified readouts on the same open infrastructure. Open, auditable, and made in Europe: less software, more biology.
Data Challenges To Multi-Omics in Clinical Practice: Lessons From ctDNA Laboratories and Clinicians
Industry Presentation Conference Room 6This presentation explores how challenges in data integration, interoperability, provenance and clinical context may affect the clinical implementation of multi-omics. The findings draw on a systematic study of ctDNA laboratories and clinicians, complemented by discussions from a multidisciplinary cancer diagnostics workshop.
Close of Day One & Networking Drinks Reception
Morning Break & Refreshments
Lunch Break
Afternoon Break & Refreshments
End of Event
Lunch Break
Morning Break & Refreshments
Breakfast Session: Investing in Precision Medicine: The Founder & Investor Perspective
Innovation PresentationCome together over breakfast to discuss how investors and VCs are identifying, funding, and supporting breakthrough science in precision medicine, alongside a first-hand founder perspective on the journey from securing investment and scaling a company
Registration Opens
.jpg?length=600&name=1048e2c3-e8c7-4b49-9c34-abc9914eac2c-2-11764368speaker_photo-Jutta-Eichler-(2).jpg)
.png?length=600&name=1.GenScriptCorporation_Logo_EN_Horizontal_FullColor%20(2).png){kind=logo}
.png?length=600&name=9eaa81ee-5bbe-4b99-86f7-23f16ccb27a8-2-5668375logo-PersonalisCorporateLogo-(2).png)
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
